FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma

N Bouchkouj, YL Kasamon, RA de Claro, B George… - Clinical Cancer …, 2019 - AACR
In October 2017, the FDA granted regular approval to axicabtagene ciloleucel, a CD19-
directed chimeric antigen receptor (CAR) T-cell therapy, for treatment of adult patients with …
被引用次数：226 相关文章

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

N Bouchkouj, YL Kasamon… - … : an official journal …, 2019 - pubmed.ncbi.nlm.nih.gov
In October 2017, the FDA granted regular approval to axicabtagene ciloleucel, a CD19-
directed chimeric antigen receptor (CAR) T-cell therapy, for treatment of adult patients with …

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.

N Bouchkouj, YL Kasamon, RA de Claro… - … Cancer Research: an …, 2018 - europepmc.org
In October 2017, the FDA granted regular approval to axicabtagene ciloleucel, a CD19-
directed chimeric antigen receptor (CAR) T-cell therapy, for treatment of adult patients with …

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

N Bouchkouj, YL Kasamon, RA de Claro… - Clinical Cancer …, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> In October 2017, the FDA granted regular
approval to axicabtagene ciloleucel, a CD19-directed chimeric antigen receptor (CAR) T-cell …